INVITATION
We kindly invite you to the scientific event organized by the Pharmacovigilance and Patient Safety Research Group, Department of Internal Medicine and Oncology, Oncology Unit, Semmelweis University and the Central and Eastern European Academy of Oncology:
1st Winter School of Pharmacovigilance and Patient Safety Research Group
Inter- and Multidisciplinary Chapters of Clinical Oncology,
Patient Safety and Pharmacovigilance
training course & conference
Date: 19th & 20th December, 2025
Venue: Central and Eastern European Oncology Academy
1125 Budapest, Diana u. 6/c
The participants will receive Certificate of Attendance upon request.
This will be a hybrid event, with the option to attend in person or participate online.
The official language of the conference is English. Participation is free of charge but requires registration.
Please send your registration to:
drugresearch.oncology@semmelweis.hu
Budapest, 10th November, 2025.
Dr. Máté Ádám Balázs Dr. Attila Marcell Szász Prof. Dr. Magdolna Dank
Secretary of the Research Group Vice-President Head of the Research Group
CEEAO Director General
PRELIMINARY PROGRAM*
1st Winter School of Pharmacovigilance and Patient Safety Research Group
Inter- and Multidisciplinary Chapters of Clinical Oncology,
Patient Safety and Pharmacovigilance*
Date: 19th December 2025 (Friday)
Day 1
|
14:00 – 14:10 |
Opening Remarks
Prof. Dr. Magdolna Dank, director general, National Institute of Oncology, Budapest, Hungary; Head of Pharmacovigilance and Patient Safety Research Group, Department of Internal Medicine and Oncology, Oncology Unit, Semmelweis University
|
|
14:10 – 14:20 |
Welcome Address
Dr. Máté Ádám Balázs, secretary, Pharmacovigilance and Patient Safety Research Group, Oncology Unit, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
|
|
14:20 – 14:30 |
Why can be a big advantage to choose scientific research work as medical student?
Devarajuly Mariyappan, student research associate, Pharmacovigilance and Patient Safety Research Group, Oncology Unit, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
|
|
14:30 – 15:00 |
Scientific writing: how to get published
Akhmedov Mobil I., oncologist PhD, M.D. Senior Researcher at the Group of High-dose chemotherapy and Bone marrow Transplantation. Department of Drug Treatment of Tumors at the P. Hertsen Moscow Oncology Research Institute – Branch of the NMRRC
|
|
15:00 – 15:30 |
Practical advice on preparing a presentation of a scientific report
Shuvaev Vasily A., hematologist Doctor of Medical Sciences Department of Hematology and Chemotherapy of the A. Tsyb Medical Radiological Research Centre – Branch of the NMRRC
|
|
15:30 – 16:00 |
Simple steps to a strong and effective science presentation
Sedova Maria V., oncologist Phd, M.D. Daycare Hospital for the Drug Treatment of tumors at the P. Hertsen Moscow Oncology Research Institute – Branch of the NMRRC
|
|
16:00 – 16:30 |
Coffee Break
|
|
16:30 – 17:00 |
History of drug antitumor treatment
Snegovoy Anton V., oncologist. Doctor of Medical Sciences Deputy Director General of the NMRRC. Head of the Department of Drug Treatment of Tumors at the N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the NMRRC
|
|
17:00 – 17:30 |
Conducting an Effective Scientific Literature Search
Péter Szluka, director, Central Library, Semmelweis University, Budapest, Hungary
|
|
17:30 – 18:00 |
Maintenance therapy in oncology. Management of adverse events during drug antitumor treatment
Snegovoy Anton V., oncologist. Doctor of Medical Sciences Deputy Director General of the NMRRC. Head of the Department of Drug Treatment of Tumors at the N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the NMRRC
|
|
18:00 – 18:10 |
Closing Remarks
|
*The organizers reserve the right to change the program.
PRELIMINARY PROGRAM*
1st Winter School of Pharmacovigilance and Patient Safety Research Group
Inter- and Multidisciplinary Chapters of Clinical Oncology,
Patient Safety and Pharmacovigilance*
Date: 20th December 2025
Day 2
|
09:00 – 09:10 |
Opening Remarks
Dr. Máté Ádám Balázs, secretary, Pharmacovigilance and Patient Safety Research Group, Oncology Unit, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
|
|
09:10 – 09:40 |
Pre-clinical animal studies – Basic research of new clinical compounds
Prof. Dr. Aleksandar Rašković, full professor, Head of the Department of Pharmacology, Toxicology and Clinical Pharmacology Medical Faculty of Novi Sad, Novi Sad, Serbia
|
|
09:40 – 10:10 |
Preclinical studies in CNS drug development
Prof. Dr. Bernadeta Sewczyk, Head of the Department of Neurobiology, May Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
|
|
10:10 – 10:40 |
Chemobrain and cognitive impairment due to oncotherapy.
Prof. Dr. Joanna Wierońska, Head of the Laboratory of Neurobiology of Psychiatric Disorders, Department of Neurobiology, May Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
|
|
10:40 – 11:10 |
Coffee Break
|
|
11:10 – 11:40 |
Myth and Facts of tumormarkers and other laboratory biomarkers in oncology
Prof. Dr. Ondrej Topolcan, Head of Central Laboratory for Immunoanalysis, Head of the Department of Immunochemistry and Biobank at the University Hospital Pilsen, Deputy Director of the Biobank at the Faculty of Medicine, Charles University in Prague, Deputy Director for Science and Research at the University Hospital Pilsen, Faculty of Medicine in Pilzen, Charles University, Czech Republic
|
|
11:40 – 12:10 |
Onco-interventions – Expanding opportunities in the everyday clinical oncology practice
|
|
12:10 – 12:20 |
Changing Landscape in Oncology Treatment and Oncotherapy
Dr. Máté Ádám Balázs, secretary, Pharmacovigilance and Patient Safety Research Group, Oncology Unit, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
|
|
12:55 – 13:05 |
Youth Researcher Student Award Ceremony
|
|
13:05 – 13:15 |
A Conclusive Case Series: Cardiotoxicity mediated by HER2-targeted therapy represents real threats in the metastatic setting
Devarajuly Mariyappan, student research associate, Pharmacovigilance and Patient Safety Research Group, Oncology Unit, Department of Internal Medicine and Oncology, Semmelweis University, Budapest
|
|
13:15 – 14:15 |
Lunch Break
|
|
14:15 – 14:45 |
Nutritional therapy – As an essential part of onco-rehabilitation
Dr. Erzsébet Pálfi, associate professor, Department of Dietetics and Nutrition Sciences, Faculty of Health Sciences, Semmelweis University, Budapest, Hungary
|
|
14:45 – 15:15 |
Perspectives for PARP1 inhibitors for the treatment of glioma and breast cancer
Dr. habil. Agnieszka Zagorska assistant professor, Department of Medicinal Chemistry, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University, Krakow, Poland
|
|
15:15 – 15:45 |
Coffe Break
|
|
15:45 – 16:15 |
Is there a role for nurses in pharmacovigilance – what can pharmacovigilance nurse mean?
Dallakoti Sraddha,– Semmelweis University, Department of Internal Medicine and Oncology, Oncology Unit, Pharmacovigilance and Patient Safety Research Group
|
|
16:15 – 16:45 |
Drug-Induced Speech Disorders – The Speech-Language Pathologist as a Potential Source of Medication Safety Insight
Ádám Attila Szücs, Center for Geriatric Care and Nursing Science, Semmelweis University, Budapest, Hungary
|
|
16:45 – 17:15 |
Intersections of Oncology and Geriatrics – Geriatric Rehabilitation and Oncology
Abu Baker, Center for Geriatric Care and Nursing Science, Semmelweis University, Budapest, Hungary
|
|
17:15 – 17:30 |
Closing Remarks
Dr. Máté Ádám Balázs, secretary, Pharmacovigilance and Patient Safety Research Group, Oncology Unit, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
|
*The organizers reserve the right to change the program.